Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 15/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2896463 | 0.81 | SLC6A9 (0.68) | SLC6A9 | |
| SCHEMBL3558262 | 0.81 | SLC6A9 (0.56) | SLC6A9 | |
| SCHEMBL2902736 | 0.80 | HPGD (0.61) | SLC6A9HPGDLMNATHRB | |
| SCHEMBL2903171 | 0.79 | SLC6A9 (0.67) | SLC6A9 | |
| SCHEMBL25276674 | 0.79 | GPR119 (0.48) | HPGDLMNATHRB | |
| SCHEMBL760752 | 0.79 | SLC6A9 (0.54) | SLC6A9 | |
| SCHEMBL25225903 | 0.78 | GPR119 (0.49) | LMNATHRB | |
| SCHEMBL2899317 | 0.78 | SLC6A9 (0.71) | SLC6A9 | |
| SCHEMBL7895891 | 0.77 | SLC6A9 (0.62) | SLC6A9HPGDLMNA | |
| SCHEMBL2904379 | 0.77 | OPRD1 (0.48) | LMNATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1831201-B1 | PIPERIDINE AND AZETIDINE DERIVATIVES AS GLYT1 INHIBITORS | MERCK SHARP & DOHME (GB) | 2010-08-04 | — | — | EP | disclosed |
| US-7655644-B2 | Piperidine and azetidine derivatives as GlyT1 inhibitors | MERCK SHARP & DOHME LIMITED (GB) | 2010-02-02 | — | — | US | disclosed |
| US-20080090796-A1 | Piperidine And Azetidine Derivatives As Glyt1 Inhibitors | MERCK SHARP & DOHME (UK) LIMITED (GB) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090796-A1 | Piperidine And Azetidine Derivatives As Glyt1 Inhibitors | SLC6A7, SLC1A1, SLC1A2 | SLC6A9 11/4885HPGD 2137/4885LMNA 4803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.